Eliocad Recherche de personnes - D-HOME-OTIK

The Market ShareA MARKET DYNAMICS SPOTLIGHT ON GLOBAL HEALTH NEWS19 AUGUST 2014 | VOL. 4, NO. 30HIV/AIDSExcellent outcomesamong people startingHIV therapy at highCD4 counts in UgandaFrom Aidsmap: “People inUganda starting ART withhigher CD4 counts canachieve excellent outcomes, investigatorsreport in AIDS. Asymptomaticadults who started therapywith a CD4 count above 350 cells/mm 3 were monitored for 12months. Almost all were retainedin care, 97% achieved an undetectableviral load, adherence wasexcellent and toxicities and sideeffectswere rare. The participantsin the study received stream-lined,nurse-led care. ‘Our results challengecurrent concerns that individualswith high CD4 + cell countmay not desire or adhere well toART, or be able to achieve robustvirologic suppression,’ write theauthors. Carter M. Aidsmap. 8 Aug2014. See: Successful antiretroviraltherapy delivery and retentionin care among asymptomaticindividuals with high CD4+T-cell counts at least 350 cells/[mu]l in rural Uganda. Jain V,Byonanebye DM, Amanyire G et al.AIDS. Advance e-pub 14 Jul 2014. nTenofovir alafenamidevs. tenofovir disoproxilfumarate in single tabletregimens for initial HIV-1therapy: a randomizedPhase 2 studyThe aim of this study inJAIDS was “to evaluate thesafety and efficacy of thenovel tenofovir prodrug, tenofoviralafenamide (TAF), as part of asingle-tablet regimen for the initialtreatment of HIV-1 infection. It wasa Phase 2, randomized, doubleblind,double-dummy, multicenter,active-controlled study in whichARV naive adults with HIV-1 RNA≥5000 copies per milliliter and aCD4 count ≥50 cells per microliterwere randomized 2:1 to receivean STR of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide(E/C/F/TAF) or elvitegravir/cobicistat/emtricitabine/tenofovirdisoproxil fumarate (E/C/F/TDF), plus placebo for 48 weeks.Results: Patients on both E/C/F/TAF (n = 112) and E/C/F/TDF(n = 58) had high rates of virologicsuppression at week 24(86.6%; 89.7%) and at week 48(88.4%; 87.9%), and had similarimprovements in CD4 at week48 (177; 204), respectively. Bothtreatments were well tolerated, andmost adverse events were selflimitingand of mild to moderateseverity. Compared with patientson E/C/F/TDF, patients on E/C/F/TAF had smaller reductions in estimatedcreatinine clearance, significantlyless renal tubular proteinuria,and smaller changes in bonemineral density for hip and spine.”Sax PE, Zolopa A, Brar I et al.JAIDS. 1 Sep 2014;67(1):52-58. nHIV treatment successeslead to new challenges,opportunities inconfronting chronic diseaseFrom Science Speaks: “ Everycontinent has seen thesuccess of [anti-HIV efforts]in dropping numbers of newinfections, dropping rates of deathfrom the disease, and longerCONTENTSn HIV/AIDS Page 1n HIV/AIDS and TB Page 3n Tuberculosis Page 4n Malaria Page 6n Cross-Cutting Issues Page 7n Of Further Interest Page 8To subscribe to The Market Share or download newissues, please visit: www.unitaid.org/themarketshareThe Market Share is prepared by Lucy Honig withsupport from UNITAID and consists of excerpts fromjournals, newspapers, blogs and other global healthpublications. The views expressed are those of theauthors of this source material and do not necessarilyrepresent the views of UNITAID. The published materialis distributed without warranty of any kind, eitherexpress or implied. UNITAID accepts no responsibilityregarding the use of the material by the reader.UNITAID Secretariat20 Avenue Appia, 1211 Geneva 27, Switzerland ,Tel. +41 22 791 1236, web: www.unitaid.org.email: unitaid@who.intproductive life spans. The newissue of JAIDS is the product of aneffort to measure and respond tothe other side of those successes:rising rates of diabetes, heartdisease, cancers, liver disease,mental illness and substanceabuse—illnesses that can becomemore and more consequentialcommon with age, with exposureto toxic ART, and in immunesystems inflamed or suppressedby HIV. They are illnesses thatwill increasingly challenge healthsystems in low and middleincome countries, and call fornew responses, authors of the 8(continued on page 2)

ON OFF S6ON OFF S7ON OFF S5ON OFF S6ON OFF S7ON OFF S5Eliocad Recherche de personnesFiche technique : F0024ARéférence(s) : 782 16/17 Date : 12/06/20024. BLICK RMS Radio Messagerie sur Site4. BLICK RMS Radio Messagerie sur Site (suite)4.1. Matériel à connecter782 16/17 Pupitre ELIOCAD4.3 Paramétrage du pupitre (suite)ON OFF S6SECI B52ON OFF S7ON OFF S54.2 Schéma de branchementCordon SUD25-SUBD9Câble non croisé SUB D25femelle - SUB D9 mâle2-2 3-315m maximumDémontage du pupitreSECI B52Configuration LEGRAND 22x2 15m2x2 900mAPG11X4 entrées alarmes NOCoffretde raccordementC9412A100TX 1 WattPupitre ELIOCAD12V12V78216/17 Clavier AQUARIUSAlimentation AlimentationAEN2T220V C9861 220V C98614.4 FonctionnalitésIls sont traduits de la manière suivante sur le bipLes états affichables sont :1. Appel malade “APP MAL”2. Alarme Biomédicale “BIOMED”3. Appel Sanitaire “APP SAN”4. Appel Radio “APP RAD”5.Tranquillisé”TRANQUIL”6. Présence Infirmière “PRE INF”7. Appel Urgent Infirmière “URG INF”8. Appels urgent infirmière + médecin “URG IF+D”9. Appels Urgent Médecin “URG DOC”Affichage des 4 premières lignes :SW1 --> 9 “ZONING”+ tris sur type d’appel, possibilitéd’avoir un tri par étage avec un seul pupitre Eliocad3

ON OFF S6ON OFF S7ON OFF S5ON OFF S6ON OFF S7ON OFF S5Eliocad Recherche de personnesFiche technique : F0024ARéférence(s) : 782 16/17 Date : 12/06/20025. BLICK DECT5.1. Matériel à connecter5. BLICK DECT (suite)5.3. Paramétrage du pupitreON OFF S6782 16/17 Pupitre ELIOCADCordon SUD25-SUBD9Câble non croisé SUB D25femelle - SUB D9 mâle2-2 3-315m maximumSECI B52Démontage du pupitreSECI B52ON OFF S7ON OFF S5Configuration LEGRAND 25.2 Schéma de branchement8PSCCFPI IW WU U8 8Pupitre ELIOCAD78216/171 à 8 bornes par RFPPrévoir 1 PS analogique par PPHPABX2x2 15mCIPALRFP 812V220VRFP2x2 15mC9861RFP RFP RFP1x2 1200m2x2 900mAlimentationCoffretde raccordement12VAlimentation220V4 entrées alarmes NOC9861C9412PPHClavier AQUARIUSAEN2X5.4 FonctionnalitésIls sont traduits de la manière suivante sur le bipLes états affichables sont :1. Appel malade “APP MAL”2. Alarme Biomédicale “BIOMED”3. Appel Sanitaire “APP SAN”4. Appel Radio “APP RAD”5.Tranquillisé”TRANQUIL”6. Présence Infirmière “PRE INF”7. Appel Urgent Infirmière “URG INF”8. Appels urgent infirmière + médecin “URG IF+D”9. Appels Urgent Médecin “URG DOC”Affichage des 4 premières lignes :SW1 --> 9 “ZONING”+ tris sur type d’appel, possibilitéd’avoir un tri par étage avec un seul pupitre Eliocad4